Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?

This phase 2 trial tests whether the immunotherapy drug cemiplimab can be used alone before surgery for certain patients with early-stage non-small cell lung cancer (NSCLC) that can be removed. The goal is to see if some patients can safely skip chemotherapy and its harsh side effects, while still achieving a successful outcome. Participants receive cemiplimab infusions, then scans to check tumor response. Depending on the response, they may proceed to surgery directly or receive additional chemo plus cemiplimab before surgery. The study focuses on patients with stage II-IIIB NSCLC that is considered resectable.